Ewa Burchardt1, Andrzej Roszak1,2. 1. Department of Radiotherapy and Oncological Gynecology, Greater Poland Cancer Centre, Poznan, Poland. 2. Department of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland.
Abstract
BACKGROUND: This article reviews the salient features of recent results of clinical studies. It puts a special emphasis on technical aspects, mechanisms of action together with radiotherapy and chemotherapy and points out areas for additional investigation. AIM: To present the current state of knowledge on hyperthermia (HT) and to highlight its role in the treatment of cervical cancer. MATERIALS AND METHODS: The literature on the clinical use of combined hyperthermia for cervical cancer was analyzed. Clinical outcomes together with the technical aspects and the role of HT were also evaluated. RESULTS: Clinically randomized trials have demonstrated benefit including survival with the addition of hyperthermia to radiation or chemotherapy in the treatment of cervical cancer without significant acute or late morbidities. The technological advances have led to an effective and safer treatment delivery, thermal treatment planning, thermal dose monitoring and online adaptive temperature modulation. CONCLUSIONS: Due to rapid development over the last decade of hyperthermia systems and new studies at the basic science and clinical level, the perception of hyperthermia as a part of multimodality treatment in cervical cancer has been changed. However, there is still a need for multicentre randomized clinical trials.
BACKGROUND: This article reviews the salient features of recent results of clinical studies. It puts a special emphasis on technical aspects, mechanisms of action together with radiotherapy and chemotherapy and points out areas for additional investigation. AIM: To present the current state of knowledge on hyperthermia (HT) and to highlight its role in the treatment of cervical cancer. MATERIALS AND METHODS: The literature on the clinical use of combined hyperthermia for cervical cancer was analyzed. Clinical outcomes together with the technical aspects and the role of HT were also evaluated. RESULTS: Clinically randomized trials have demonstrated benefit including survival with the addition of hyperthermia to radiation or chemotherapy in the treatment of cervical cancer without significant acute or late morbidities. The technological advances have led to an effective and safer treatment delivery, thermal treatment planning, thermal dose monitoring and online adaptive temperature modulation. CONCLUSIONS: Due to rapid development over the last decade of hyperthermia systems and new studies at the basic science and clinical level, the perception of hyperthermia as a part of multimodality treatment in cervical cancer has been changed. However, there is still a need for multicentre randomized clinical trials.
Authors: J van der Zee; D González González; G C van Rhoon; J D van Dijk; W L van Putten; A A Hart Journal: Lancet Date: 2000-04-01 Impact factor: 79.321
Authors: W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: Martine Franckena; Ludy C Lutgens; Peter C Koper; Catharina E Kleynen; Elsbieta M van der Steen-Banasik; Jan J Jobsen; Jan Willem Leer; Carien L Creutzberg; Michel F Dielwart; Yvette van Norden; Richard A M Canters; Gerard C van Rhoon; Jacoba van der Zee Journal: Int J Radiat Oncol Biol Phys Date: 2008-11-05 Impact factor: 7.038
Authors: Ludy Lutgens; Jacoba van der Zee; Madelon Pijls-Johannesma; Danielle Fm De Haas-Kock; Jeroen Buijsen; Ghislaine Apg van Mastrigt; Guido Lammering; Dirk K M De Ruysscher; Philippe Lambin Journal: Cochrane Database Syst Rev Date: 2010-03-17
Authors: Marloes IJff; Gregor G W van Bochove; Denise Whitton; Roy Winiarczyk; Celina Honhoff; Hans Rodermond; Johannes Crezee; Lukas J A Stalpers; Nicolaas A P Franken; Arlene L Oei Journal: Cancers (Basel) Date: 2021-04-26 Impact factor: 6.639